Lexaria Bioscience Says Its Second Weight Loss Drug Human Study Showed No Adverse Events
Lexaria Bioscience Says Its Second Weight Loss Drug Human Study Showed No Adverse Events
Lexaria生物科技表示，其第二种减肥药的人体研究显示没有不良事件。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册